Patient Voice: Asking and Listening to the Patient
Successful clinical trial recruitment requires a thorough understanding of the target patient profile, and a key factor within this profile is patient motivation. What drives a patient to consider, then subsequently inquire, prescreen, and finally consent and participate in a trial? While these motivations will vary by previous research experience, indication or condition, study type, patient demographics, and other elements, common themes often emerge when one speaks to patients directly about their reasoning. The lesson? Always ask the patients. Their reasons can surprise even the most seasoned clinical research professional.
A series of interviews were conducted in the spring of 2018 as a pulse-check on existing hypotheses around what motivates the people who chose to participate in multiple trials (not concurrently, of course). Seven patients (4 men, 3 women) from five sites within the PMG Research integrated site network were interviewed by phone. Expansion to a larger patient population is planned for Q318 to validate the common response themes that have been identified
Patients looking for a better course of treatment
The interviews ultimately validated the theory that while participants are driven to consider research for various personal reasons, a primary reason remains a dissatisfaction with the current course of their condition and a motivation to find something better. However, only two of seven patients interviewed were told about clinical research by their physician (who also happened to be the Principal Investigator on the study referenced); the others sought it out on their own. Even when aware that the study may have a placebo component, uncomfortable procedures, or inconvenient visit schedules, the overall research experience outweighed the discomforts for many.
When asked what advice they would give to someone considering research for the first time, the response was an overwhelming “Do it!” With a positive experience behind them, participants can become the strongest advocates for clinical research, and they can often offer insights into small improvements in trial design that can make the difference between a consent and a decline; between completion and drop-out; between compliance and lost to follow-up.
The importance of positive personal interaction
The importance of the experience with the study team – from the receptionist, to the phlebotomist, to the research coordinator and investigators - cannot be overstated. It is because of these meaningful relationships that patients choose to look past the challenges and find ways to participate. This is not to say, however, that a positive relationship at the site level can make up for a protocol that was not designed with the patient in mind. One must wonder how many tertiary and exploratory endpoints caused patients to say “Too many needles!” while begging for a functioning e-diary during a long-term outcomes study.
As research professionals and innovators we have a call to improve the clinical research ecosystem and implement truly patient-centric trials; we must listen to the suggestions – even those given tongue in cheek – from those without whom we’d have no trials all.
For more information on how PMG Research, part of ICON Site & Patient Recruitment engages with patients to improve the patient experience and engagement contact Kristin Kinlaw, Director of Communications at PMG Research at kkinlaw@pmg-research.com.
Patient Voice
Read our article to explore motivations & perceptions of experienced research participants
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel